Early three-month report of amniotic bladder therapy in patients with interstitial cystitis/bladder pain syndrome

Madan, Raghav; Radoiu, Codrut; Liaw, Aron; Lucas, Steven M.; Hamada, Alaa; Dhar, Nivedita

doi:10.1007/s11255-023-03652-8

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Amniotic bladder therapy is a new treatment option under exploration with the goal of healing the urothelial barrier in IC/BPS patients. An ongoing clinical trial has provided an update that three months following intra-detrusor injections of 100 mg micronized amniotic membranes, patients reported improved voiding symptoms and reduced bladder pain (Madan et al, 2023). While research into this therapy is limited due to its novelty, the proposed mechanism of action is that amniotic membranes help promote glycoprotein and hyaluronic acid expression, reduce inflammation, and promote nerve regeneration (Madan et al, 2023).…”

Section: The Latest Therapeutic Advances and Experimental Targetsmentioning

confidence: 99%

Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions

Ashraf,

Clarkson,

Malykhina

2024

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Urologic Chronic Pelvic Pain Syndrome (UCPPS) is a painful chronic condition with persistent pain originating from the pelvis that often leads to detrimental lifestyle changes in the affected patients. The syndrome develops in both sexes, with an estimated prevalence of 5.7% to 26.6% worldwide. This narrative review summarizes currently recommended therapies for UCPPS, followed by the latest animal model findings and clinical research advances in the field. The diagnosis of UCPPS by clinicians has room for improvement despite the changes in the past decade aiming to decrease the time to treatment. Therapeutic approaches targeting growth factors (i.e., NGF, VEGF), amniotic bladder therapy and stem cell treatments gain more attention as experimental treatment options for UCPPS. The development of novel diagnostic tests based on the latest advances in urinary biomarkers would be beneficial to assist with the clinical diagnosis of UCPPS. Future research directions should address the role of chronic psychological stress and the mechanisms of pain refractory to conventional management strategies in UCPPS etiology. Testing the applicability of cognitive behavioral therapy in this cohort of UCPPS patients might be promising to increase their QoL. The search for novel lead compounds and innovative drug delivery systems requires clinically relevant translational animal models. The role of autoimmune responses triggered by environmental factors is another promising research direction to clarify the impact of the immune system in UCPPS pathophysiology. SIGNIFICANCE STATEMENTThis minireview provides an up-to-date summary of the therapeutic approaches for UCPPS with focus on recent advancements in the clinical diagnosis and treatments of the This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward.

show abstract

Section: The Latest Therapeutic Advances and Experimental Targetsmentioning

confidence: 99%

Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions

Ashraf,

Clarkson,

Malykhina

2024

J Pharmacol Exp Ther

View full text Add to dashboard Cite

show abstract

Effect of Amniotic Bladder Therapy on Female Sexual Function of Patients with Interstitial Cystitis/Bladder Pain Syndrome: Early 3-Month Report

Wittenberg,

Ross,

Emrich Accioly

et al. 2024

Journal of Gynecologic Surgery

View full text Add to dashboard Cite

Treatment of chronic post-radiation cystitis with trans-urethral amniotic bladder therapy appears durable at 9 months: A clinical study

Lutchka,

Vercnocke,

Fisher

et al. 2024

Urologia

Self Cite

View full text Add to dashboard Cite

Purpose: Chronic radiation cystitis (CRC) develops after radiation therapy and can present with symptoms like urinary frequency, urgency, pelvic pain, and nocturia. We have previously reported that amniotic bladder therapy (ABT) provides symptomatic improvement in refractory CRC patients for up to 3 months. Herein, we evaluated the durability of ABT up to 6 months. Materials and methods: CRC patients recalcitrant to previous treatments received ABT comprised of intra-detrusor injections of 100 mg micronized AM diluted in 10 mL 0.9% preservative-free sodium chloride. Clinical evaluation and questionnaires (Interstitial Cystitis Symptom Index (ICSI), Interstitial Cystitis Problem Index (ICPI), Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-SS), Overactive Bladder (OAB) Assessment Tool, SF-12 Health Survey) were repeated at pre-op and 2, 4, 8, 12, 16, 20, 24, and 36 weeks post-injection. Results: Five consecutive patients with a mean age of 64.4 ± 20.1 years with a median CRC duration of 10 years were included and followed for 6 months. After ABT, the lower urinary tract symptoms improved as early as 2 weeks and were maintained up to 20 weeks. BPIC significantly improved from 36.6 ± 1.1 at baseline to 12.6 ± 1.5 at 16 weeks and 13.8 ± 2.9 at 20 weeks. At 24 and 36 weeks, the improvement was maintained in four (80%) of the five patients (BPIC = 13.8 ± 1.0). Uroflow assessment showed voiding volume improved two-fold in four of the five patients at 24 weeks compared to baseline. Conclusion: Our data suggest that a significant number of CRC patients may have durable benefit after ABT. Despite this, some of them can show symptoms rebound at 24 weeks.

show abstract

Early three-month report of amniotic bladder therapy in patients with interstitial cystitis/bladder pain syndrome

Cited by 3 publications

References 26 publications

Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions

Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions

Effect of Amniotic Bladder Therapy on Female Sexual Function of Patients with Interstitial Cystitis/Bladder Pain Syndrome: Early 3-Month Report

Treatment of chronic post-radiation cystitis with trans-urethral amniotic bladder therapy appears durable at 9 months: A clinical study

Contact Info

Product

Resources

About